Table 2.
Demographic and clinical characteristics of the hypertensive patients aged ≥75 years in the clinical trial study
| Placebo group (n = 109) | Rosuvastatin group (n = 118) | P value | |
|---|---|---|---|
| Clinical parameters | |||
| Female (n [%]) | 52 (47.7) | 57 (48.3) | 0.928 |
| Age (years) | 78.48 ± 2.58 | 78.24 ± 2.35 | 0.465 |
| Current smoking (n [%]) | 28 (25.7) | 23 (19.5) | 0.264 |
| Alcohol consumption (n [%]) | 34 (31.2) | 33 (28.0) | 0.594 |
| Body mass index (kg/m2) | 23.57 ± 2.21 | 23.94 ± 2.49 | 0.226 |
| Heart rate (bpm) | 67.21 ± 6.41 | 67.51 ± 5.45 | 0.706 |
| SBP (mm Hg) | 157.23 ± 9.50 | 156.80 ± 9.74 | 0.735 |
| DBP (mm Hg) | 71.14 ± 7.21 | 70.76 ± 7.35 | 0.699 |
| Biochemical parameters | |||
| TCHO (mmol/L) | 5.08 ± 0.66 | 5.12 ± 0.69 | 0.696 |
| TG (mmol/L) | 1.51 ± 0.39 | 1.48 ± 0.39 | 0.625 |
| HDL-C (mmol/L) | 1.12 ± 0.19 | 1.17 ± 0.19 | 0.061 |
| LDL-C (mmol/L) | 3.28 ± 0.72 | 3.28 ± 0.75 | 0.989 |
| FPG (mmol/L) | 5.70 ± 0.66 | 5.62 ± 0.67 | 0.333 |
| Brain magnetic resonance imaging | |||
| WMH (mL) | 6.57 (5.16, 8.11) | 6.93 (4.87, 8.03) | 0.907 |
| WMH-to-ICV ratio (%) | 0.54 (0.40, 0.69) | 0.54 (0.40, 0.66) | 0.871 |
| Prevalence of Fazekas scale ≥2 (n [%]) | 27 (24.8) | 21 (17.8) | 0.199 |
| Prevalence of lacunes (n [%]) | 16 (14.7) | 13 (11.0) | 0.409 |
| Prevalence of Virchow-Robin spaces (n [%]) | 12 (11.0) | 11 (9.3) | 0.674 |
| Prevalence of microbleeds (n [%]) | 13 (11.9) | 9 (7.6) | 0.274 |
Data are expressed as mean ± standard deviation, median with interquartile range, or numbers with percentages. Abbreviation list: SBP indicates systolic blood pressure; DBP, diastolic blood pressure; TCHO, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; FPG, fasting plasma glucose; WMH, white matter hyperintensities; ICV, intracranial volume